Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. FDA Chief Gottlieb Resigns

Yasmeen Abutaleb  |  March 5, 2019

WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs.

The U.S. Department of Health and Human Services (HHS), which oversees the FDA, announced Mr. Gottlieb’s resignation on Tuesday, March 5.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Mr. Gottlieb was well regarded and won bipartisan support for his efforts to curb the use of flavored e-cigarettes by youths, speed approval times for cheap generic medicines to increase competition and bring down prescription drug prices and boost the use of cheaper versions of expensive biotech medicines, called biosimilars.

“Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use,” HHS Secretary Alex Azar said in a statement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA did not respond to a request for comment.

The Washington Post first reported on Tuesday that Mr. Gottlieb planned to resign.

“Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!” Republican President Donald Trump wrote on Twitter on Tuesday.

In his resignation letter, Mr. Gottlieb touted several of the agency’s initiatives, including efforts to curb tobacco use, decrease the rate of opioid addiction, speed up approval of generic drugs and streamline the process for novel medical technologies such as gene therapy.

“I’m immensely grateful for the opportunity to help lead this wonderful agency, for the support of my colleagues, for the public health goals we advanced together, and the strong support of @SecAzar and @realDonaldTrump—This has been a wonderful journey and parting is very hard,” he wrote on Twitter, referring to Mr. Azar and President Trump by their Twitter handles.

Curbing E-Cigarette Use
Mr. Gottlieb’s signature policy initiative was his effort to reduce teen e-cigarette use. He expressed concern over the rise in the number of youths using flavored e-cigarettes after preliminary federal data showed teenage use had surged by more than 75% since last year, which the FDA described as an epidemic.

Under Mr. Gottlieb, the FDA issued a ban on the sale of fruit- and candy-flavored electronic cigarettes in convenience stores and gas stations, meaning only tobacco, mint and menthol flavors can be sold at these outlets.

Page: 1 2 | Single Page
Share: 

Filed under:Professional Topics Tagged with:FDAFDA Commissioner Scott GottliebFood and Drug AdministrationU.S. Food and Drug Administration (FDA)

Related Articles
    Lightspring / shutterstock.com

    Recent Research Probes Smoking & the Risk for Autoimmune Disease

    March 18, 2019

    It’s no secret to any health professional, including rheumatologists, that smoking cigarettes or using other tobacco-based products is unhealthy. Yet how does smoking specifically affect rheumatic diseases, and what are some of the newest findings in this area? What role do e-cigarettes have in the smoking risk landscape? Those are the sorts of questions asked…

    Tobacco and Medicine: A Hazy Relationship

    January 1, 2015

    How tobacco companies tapped physicians to bolster hollow marketing claims to sell cigarettes

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief

    March 13, 2017

    WASHINGTON (Reuters)—U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences